MedTrace Logo

A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia

NCT06853444 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2025-05-16

No results posted yet for this study

Summary

This is a multicenter, open-label Phase1/2 study aimed at evaluating the safety, tolerability, pharmacokinetic (PK) profile, pharmacodynamics (PD), immunogenicity, and preliminary efficacy of ESG206. The study will be conducted in patients with primary immune thrombocytopenia.

Conditions

  • Immune Thrombocytopenia (ITP)

Interventions

DRUG

ESG206

Administered via intravenous (IV) infusion

DRUG

ESG206

Administered via intravenous (IV) infusion

DRUG

ESG206

Administered via intravenous (IV) infusion

DRUG

ESG206

Administered via intravenous (IV) infusion

Sponsors & Collaborators

  • Shanghai Escugen Biotechnology Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Ming Hou, PhD · Qilu Hospital of Shandong University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-08
Primary Completion
2026-03-31
Completion
2027-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06853444 on ClinicalTrials.gov